Literature DB >> 27656524

Assessment of Portal Venous and Hepatic Artery Haemodynamic Variation in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients.

Padhmini Balasubramanian1, Vinoth Boopathy2, Ezhumalai Govindasamy3, Basavaiya Prabhu Venkatesh4.   

Abstract

INTRODUCTION: Non-Alcoholic Fatty Liver Disease (NAFLD) has various spectrums of liver diseases like isolated fatty liver, steatohepatitis and cirrhosis usually progressing in a linear fashion. In this process they are known to cause certain haemodynamic changes in the portal flow and hepatic artery flow. AIM: The aim of the study was to study these haemodynamic changes in patients with NAFLD and to correlate it with the disease severity.
MATERIALS AND METHODS: Ninety patients diagnosed to have NAFLD based on ultrasound abdomen (30 each in grade1, grade2 and grade3 NAFLD) and 30 controls (Normal liver on ultrasound abdomen) were subjected to portal vein and hepatic artery Doppler study. Peak maximum velocity (Vmax), Peak minimum velocity (Vmin), Mean flow velocity (MFV), and Vein pulsality index (VPI) of the portal vein and hepatic artery resistivity index (HARI) of the hepatic artery were the doppler parameters which were assessed. Liver span was also assessed both for the fatty liver and controls.
RESULTS: The mean Vmax, Vmin, MFV and VPI of the portal vein in patients with NAFLD was 12.23±1.74cm/sec, 9.31±1.45cm/sec, 10.76±1.48cm/sec, and 0.24±0.04 as compared to 14.05±2.43cm/sec, 10.01±2.27cm/sec, 12.23±2.47cm/sec, 0.3±0.08 in controls respectively. All these differences were statistically significant except for Vmin. The Mean HARI in patients with fatty liver was 0.65±0.06 when compared to controls of 0.75±0.06 (p=0.001). HARI (r-value of -0.517) had a better negative correlation followed by VPI (r-value of -0.44) and Vmax (r-value of -0.293) with the severity of NAFLD. MFV had a very weak negative correlation (r-value of -0.182) with the severity of NAFLD.
CONCLUSION: The Vmax, MFV, VPI and HARI were significantly less when compared to controls suggesting a reduced portal flow and an increased hepatic arterial flow in patients with NAFLD. Among the parameters, HARI correlated better with the severity of NAFLD followed by VPI.

Entities:  

Keywords:  Hepatic artery resistivity index; Portal doppler; Portal vein pulsality index

Year:  2016        PMID: 27656524      PMCID: PMC5028471          DOI: 10.7860/JCDR/2016/20697.8267

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  23 in total

1.  Correlation of hepatic vein Doppler waveform and hepatic artery resistance index with the severity of nonalcoholic fatty liver disease.

Authors:  Amir Reza Mohammadinia; Khadijeh Bakhtavar; Nasser Ebrahimi-Daryani; Peiman Habibollahi; Mohammad Reza Keramati; Seyed Mohammad Fereshtehnejad; Sina Abdollahzade
Journal:  J Clin Ultrasound       Date:  2010-09       Impact factor: 0.910

2.  Observer variability in echo-Doppler measurements of portal flow in cirrhotic patients and normal volunteers.

Authors:  C Sabbá; G G Weltin; D V Cicchetti; G Ferraioli; K J Taylor; T Nakamura; F Moriyasu; R J Groszmann
Journal:  Gastroenterology       Date:  1990-06       Impact factor: 22.682

3.  Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver.

Authors:  Levent Oguzkurt; Tulin Yildirim; Dilek Torun; Fahri Tercan; Osman Kizilkilic; E Alp Niron
Journal:  Eur J Radiol       Date:  2005-05       Impact factor: 3.528

4.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.

Authors:  Stephen A Harrison; Sigurd Torgerson; Paul H Hayashi
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

Review 5.  The global impact of hepatic fibrosis and end-stage liver disease.

Authors:  Young-Suk Lim; W Ray Kim
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

6.  Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey.

Authors:  Shivaram Prasad Singh; Sachidananda Nayak; Manorama Swain; Niranjan Rout; R N Mallik; Omprakash Agrawal; Chudamani Meher; Mvk Rao
Journal:  Trop Gastroenterol       Date:  2004 Apr-Jun

7.  Prevalence of non-alcoholic fatty liver disease: population based study.

Authors:  Deepak Amarapurkar; Prafull Kamani; Nikhil Patel; Parijat Gupte; Pravin Kumar; Subhash Agal; Rajiv Baijal; Somesh Lala; Dinesh Chaudhary; Anjali Deshpande
Journal:  Ann Hepatol       Date:  2007 Jul-Sep       Impact factor: 2.400

8.  Portal vein hemodynamics in patients with non-alcoholic fatty liver disease.

Authors:  Besir Erdogmus; Ali Tamer; Ramazan Buyukkaya; Burhan Yazici; Ayla Buyukkaya; Esin Korkut; Aytekin Alcelik; Ugur Korkmaz
Journal:  Tohoku J Exp Med       Date:  2008-05       Impact factor: 1.848

9.  Liver hemodynamic patterns in nonalcoholic steatosis: Doppler ultrasonography and histological evaluation.

Authors:  Maria L Gonçalves Dos Reis Monteiro; Valéria Ferreira De Almeida E Borges; Tânia Machado De Alcântara; Lúcio Borges De Araújo; Conceição De Fátima Pinheiro; Angélica Lemos Debs Diniz
Journal:  Minerva Gastroenterol Dietol       Date:  2016-03

10.  Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.

Authors:  V Mohan; S Farooq; M Deepa; R Ravikumar; C S Pitchumoni
Journal:  Diabetes Res Clin Pract       Date:  2009-01-24       Impact factor: 5.602

View more
  2 in total

1.  Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease.

Authors:  Masoud Baikpour; Arinc Ozturk; Manish Dhyani; Nathaniel D Mercaldo; Theodore T Pierce; Joseph R Grajo; Anthony E Samir
Journal:  AJR Am J Roentgenol       Date:  2020-01-15       Impact factor: 3.959

2.  Portal Venous Pulsatility Index as a predictor of fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Shisheng Lu; Robyn Archard; Linda Mcleod; Angus Banh; Danny Con; Zaid Ardalan; Numan Kutaiba
Journal:  Australas J Ultrasound Med       Date:  2021-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.